<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074538</url>
  </required_header>
  <id_info>
    <org_study_id>CRCCZ-ncrcc</org_study_id>
    <nct_id>NCT04074538</nct_id>
  </id_info>
  <brief_title>the National Colorectal Cancer Cohort (NCRCC) Study: National Colorectal Cancer Research Consortium</brief_title>
  <official_title>The National Colorectal Cancer Cohort Study-Precision Medical Research in Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ding Ke-Feng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanxi Province Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital of Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NCRCC study is a national prospective cohort study including colorectal cancer screening
      population and stage Ⅰ-Ⅳ colorectal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NCRCC study is a large-scale multicenter study which includes 16 hospitals and research
      centers, establishing a national cohort which consists of two subcohorts (CRC Screening
      Cohort and Colorectal Cancer Patient Cohort).

        1. To assess risk factors for colorectal cancer and evaluate risk prediction model of
           colorectal cancer to identify the high-risk population.

        2. To discover, test and validate new biological markers (e.g. genetic, epigenetic,
           transcriptomic, metabolomics, proteomic and metagenomics biomarkers) for early
           diagnosis, prediction of clinical outcomes (e.g. therapeutic response, toxicity,
           surgical complications) and survivorship endpoints (e.g. recurrence, survival, quality
           of life, second primary cancer).

        3. To estimate associations of epidemiological determinants (e.g. medication and supplement
           use, diet, lifestyle pattern) with clinical outcomes and survivorship endpoints among
           CRC patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Anticipated">December 2035</completion_date>
  <primary_completion_date type="Anticipated">December 2035</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>colorectal cancer incidence</measure>
    <time_frame>up to 15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free and overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrence/metastasis</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adenoma or advanced adenoma incidence</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of treatment-related toxicities characterized by the Common Toxicity Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second primary cancer incidence</measure>
    <time_frame>up to 15 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">55000</enrollment>
  <condition>Colorectal Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin fixed and paraffin embedded (FFPE) and fresh frozen tissue (multiple
      sources/locations) from the tumor, blood, urine, feces
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NCRCC study consists of two subcohorts (CRC Screening Cohort and Colorectal Cancer Patient
        Cohort).

        CRC Screening Cohort is a population-bsaed study. All aged 40-74 years old individuals
        without prior colorectal cancer or bowel resection are recruited.

        All consecutive patients who were newly diagnosed with primary invasive or metastatic
        colorectal cancer are eligible for Colorectal Cancer Patient Cohort.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women

          -  Mentally/physically able to consent and participate

          -  Subjects aged ≥18 years old (Colorectal Cancer Patient Cohort, CRCPC), age 40-74 years
             (CRC Screening Cohort, CRCSC)

          -  Newly-diagnosed colon and rectal cancer for stages Ⅰ-Ⅳ (CRCPC)

        Exclusion Criteria:

          -  A history of colorectal cancer or bowel resection

          -  Non-Chinese speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ke-feng Ding, PhD/MD</last_name>
    <phone>86-571-87784827</phone>
    <email>dingkefeng@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310999</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke-Feng Ding, PhD/MD</last_name>
      <phone>86-571-87784827</phone>
      <email>dingkefeng@zju.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ke-Feng Ding, PhD/MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zheng Zhaoxu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Ziqiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pan Zhizhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Ye</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Ding Ke-Feng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>cohort study</keyword>
  <keyword>CRC screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

